Steven Cohen X4 Pharmaceuticals, Inc Transaction History
Point72 Asset Management, L.P.
- $36.6 Billion
- Q3 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 625,052 shares of XFOR stock, worth $218,768. This represents 0.0% of its overall portfolio holdings.
Number of Shares
625,052
Previous 543,084
15.09%
Holding current value
$218,768
Previous $314,000
33.12%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding XFOR
# of Institutions
104Shares Held
100MCall Options Held
213KPut Options Held
50.6K-
Bain Capital Life Sciences Investors, LLC Boston, MA16.9MShares$5.92 Million2.03% of portfolio
-
Nea Management Company, LLC Timonium, MD15MShares$5.25 Million0.77% of portfolio
-
Black Rock Inc. New York, NY10.7MShares$3.74 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.44MShares$2.95 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.13MShares$2.5 Million0.11% of portfolio
About X4 Pharmaceuticals, Inc
- Ticker XFOR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,646,096
- Market Cap $24M
- Description
- X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...